We sought to determine the accuracy with which Medicare billing data documents elderly Medicare cancer patients' receipt of common multiagent chemotherapy regimens.
BACKGROUND
Medicare spent nearly a billion dollars in 2002 on chemotherapy for newly diagnosed breast, colorectal, and lung cancer patients alone, but surprisingly little is known about the extent to which cancer chemotherapies help or harm such elderly patients. 1 This unsettling paradox is the direct result of the well-described under-enrollment of elderly patients on the clinical trials of chemotherapy. [2] [3] [4] In the absence of trials with representative patients, treating oncologists, patients, and policy makers must extrapolate results of clinical trials that were conducted on younger and comparatively healthier individuals. Surprisingly, basic results of this common extrapolation are unknown.
Because Medicare reimburses for intravenous administration of chemotherapy, Medicare claims are a potential source of observational data that could be used to begin to fill this knowledge gap. Other sources of potential information include other large data sources like National Cancer Data Base 5 and smaller sources like individual hospital cancer registry information linked to medical record and billing information. 6 Prior work has shown that Centers for Medicare and Medicaid Services (CMS) claims are highly valid measures of a number of cancer therapies 7, 8 including intravenous chemotherapy use among elderly Medicare beneficiaries and that the Health Care Financing Administration Common Procedure Code (HCPC) J codes are highly valid markers of individual chemotherapy agents administered to these patients. 9, 10 However, it is not known if standard chemotherapy regimens that are composed of multiple drugs administered on specific schedules (ie, on relative days) are equally as well reflected in CMS claims.
We sought to determine the sensitivity of Medicare claims at detecting five standard multiagent chemotherapy regimens among elderly Medicare patients who were known to have been treated with the regimens on clinical trials.
METHODS

Data and Cohorts CALGB Studies Data
We used clinical trial data from the Cancer and Leukemia Group B (CALGB) to identify cancer site, stage, and treatment-specific cohorts of clinical trial patients treated in the experimental setting with one of five standard first-line chemotherapy regimens. The CALGB, now a part of the Alliance for Clinical Trials in Oncology, was a National Cancer Institute sponsored cooperative oncology research group which represented a network of over 3000 physicians from 29 academic medical centers and 225 community hospitals. Members of multimodality treatment programs in seven disease areas developed therapeutic trials, which were then be opened for patient accrual at CALGB institutions. Data from the trials were collected and maintained centrally at the CALGB Statistical Center. Trial data were analyzed and results disseminated in manuscripts published in medical journals. Among the variables common to all therapeutic trials are registration information which includes: study number, subject identifiers, demographic and disease information, treatment information (eg, drugs administered, dates of treatment, doses of therapy), and survival endpoints.
Medicare Data
Medicare is a federally sponsored health insurance program administered by the CMS whose beneficiaries include more than 96% of all US citizens aged 65 and older. 11 CMS maintains billing records of outpatient, inpatient, home health, hospice, durable medical equipment (DME), and other claims for all beneficiaries not enrolled in risk contract health maintenance organizations (HMOs). To determine the study population's use of chemotherapy, we studied five types of Medicare files: the denominator file, the Medicare Provider Analysis and Review (MEDPAR) file; the Outpatient Standard Analytic File (OUTPT); the National Claims History (NCH) file, and the DME file. Of note, Medicare reimburses providers for costs associated with clinical trials including those of drugs and drug combinations that have been previously established to be standards of care. All regimens we studied were standard chemotherapy regimens at the time of trial enrollment.
Cohort Construction
We identified all 837 study subjects aged 65 or older at the time of enrollment onto one of six CALGB trials that contained one of the multidrug chemotherapy regimens of interest. Table 1 lists the six study numbers, drugs, and schedules as well as the tumor site-specific, stage-specific, and histology-specific cohorts. The cohorts represent patients with limited and extensive stage small-cell lung cancers treated with cisplatin and etoposide (CDDP/VP16); stage IIIB or IV non-small-cell lung cancer treated with carboplatin and paclitaxel; stage II or III colon cancer treated with fluorouracil and leucovorin (5FU/LV); stage IV colorectal cancer treated with a combination of 5FU/LV and irinotecan (FOLFIRI); and locoregional breast cancer treated with adjuvant doxorubicin and cyclophosphamide (AC). We linked the cohorts' CALGB clinical trial data (eg, demographic information, information pertaining to chemotherapy administration) to their CMS Medicare claims files (ie, denominator, NCH, OUTPT, MEDPAR, and DME files) from the corresponding calendar period using social security numbers. We were able to match 80% (673/837) of the participants to Medicare files. Among these 673 eligible patients, 128 were removed because they were not eligible for Medicare parts A and B during the observation period; 94 because of enrollment in HMOs whose claims were not processed through CMS; 42 because they were treated at facilities that do not bill Medicare; three because they were never treated on the CALGB trial after randomization; and 52 because their first chemotherapy was delivered in the inpatient setting, a situation in which individual agents are not discernible. The final analytic sample consisted of 354 elderly Medicare patients treated on six CALGB clinical trials with five standard first-line multiagent chemotherapy regimens who were at risk for potential ambulatory chemotherapy treatment. Figure 1 represents a schema of the cohort formation.
Variables
We developed coding algorithms that utilized specific Medicare files, codes, and data fields to determine whether individual drugs were administered (Table 2 ) and if so the drug billing date. Because all five of the standard multidrug regimens of interest required that more than one drug be given on the same day (ie, day 1 of each cycle), we similarly required that the chemotherapy agents identified in Medicare files be billed on the same day for the multidrug regimen to be considered "received." The focus on day 1 is consistent with an "intent to treat" approach to clinical care. The observation period was the first day of the month and year in which the patient was registered onto the CALGB trial (or the first day treated according to CALGB if that date preceded registration) plus 90 days. Before the era of online registration for specific studies, patients were allowed to receive protocol treatment before registering if treatment needed to occur immediately and the registration telephone line was closed. The sensitivity of the claims using 30-, 60-, 90-, and 120day time windows (from the date of registration) were each empirically evaluated and the 90-day time window was associated with a slightly higher sensitivity than the 30-and 60-day windows, but not lower than the 120-day window. We also used CALGB and Medicare data to obtain information pertaining to patients' demographic and disease attributes.
Statistical Analyses
The CALGB treatment information was considered the gold-standard against which to calculate the sensitivity of the CMS multiagent chemotherapy algorithms. Sensitivity is defined as the proportion of the patients known (according to CALGB data) to have been treated with the multiagent chemotherapy regimen of interest who are correctly identified through CMS claims as having received it during the observation period. We calculate sensitivity by dividing the number of patients who were known to have received the chemotherapy regimen of interest per CALGB data who also had Medicare claims indicating receipt of the chemotherapy of interest by the number patients who were known to have received the chemotherapy of interest per CALGB files. Exact binomial confidence intervals were calculated for each estimate. Because all patients were treated with chemotherapy, we cannot calculate specificity of CMS multiagent chemotherapy algorithms. However, prior research has shown Medicare For each of the 3 standard multiagent regimens listed above, all the drugs in the regimen were required to be administered on day 1. For FOLFIRI drugs 1-3 needed to appear on day 1, but the requisite DME codes could occur anytime between day 1 À30 days to day 1 +7 days to receive credit. Conversely, for 5FU/LV there may not be the described DME codes between day 1 À 30 days to day 1 +7 days to receive credit for drugs 1 and 2 as such codes indicate continuous infusion 5FU rather than bolus as specified by the study. HCPC, Health Care Financing Administration Common Procedure Codes; NCH, National Claims History; OUTPT, Outpatient. chemotherapy claims, including individual agents, to be highly specific. 18 This research was approved by the Duke University, Harvard Medical School, and Massachusetts General Hospital institutional review boards and conducted in compliance with their regulations. All analyses were done using STATA 10 (College Station, TX). Table 3 describes the demographic and disease characteristics of the sample. Using a broad algorithm of chemotherapy ascertainment, 18 we found that 92% (375/406) of patients at risk for having Medicare chemotherapy claims had at least 1 claim for "chemotherapy" during the observation period. Thirteen percent (52/406) of patients seemed to have received their first chemotherapy in the hospital setting, a situation in which individual drugs are not observable. As shown in Table 3 , patients who received their first cycle of clinical trial therapy in the inpatient setting had a poorer performance status than those who were first treated in the ambulatory setting and were also more likely to be receiving CDDP/VP16 for small-cell lung cancer than other therapies. The remaining patients (N = 354) were considered "at risk" for having Medicare claims documenting the specific multiagent chemotherapy regimens delivered through the clinical trial. Table 4 describes the sensitivity of CMS-based algorithms for ascertaining administration of each multiagent regimen in the ambulatory setting. The overall sensitivity of CMS ambulatory claims for documenting treatment with the correct drugs and on the correct schedule (ie, all drugs had to be billed on the same day) was 78% (275/354). The sensitivity varied little by treatment regimen. For carboplatin and paclitaxel the sensitivity was 83% (49/59), 5FU/LV 80% (73/ 91), FOLFIRI 76% (26/34), AC 75% (33/44), and CDDP/ VP16 75% (94/126).
RESULTS
Appendix A contains a detailed breakdown of the counts of the CALGB Medicare patients according to setting of treatment with chemotherapy, drugs ascertained for each regimen and the Medicare file sources of the patient counts.
DISCUSSION
This study shows that for elderly Medicare beneficiaries with breast, colorectal cancer, and lung cancer who were treated with one of five standard multiagent chemotherapy regimens on one of six phase III CALGB trials, contemporaneous Medicare claims files reflect the clinical trial therapies, on average, 78% of the time, with very consistent results across a variety of regimens. Our findings suggest that an algorithmic approach to identifying multiagent treatment regimens, requiring specific drugs (and routes of administration) that appear in the claims on the same day (or in the case of continuous infusion 5FU) within a defined billing interval surrounding day may be useful in identifying at least three quarters of patients treated with the standard multiagent chemotherapy regimens in CMS-based data sources. The algorithms could allow researchers to identify Medicare patients who were treated with standard multidrug combination chemotherapy regimens to ask and answer a variety of questions relevant to population health and health care policy. For example, researchers may compare survival of cancer site, stage, and histology-matched cohorts of patients treated with one common multiagent chemotherapy regimen versus another. As such our findings may accelerate comparative effectiveness research which in turn may inform clinical care and health care policy.
There are important caveats to this work. The results show that the sensitivity is not perfect. For example, the HCPC-based FOLFIRI algorithm we developed will miss 24% of patients treated with FOLFIRI. Among those FOLFIRI patients we "missed" with our algorithm two of the 34 (0.6%) patients seemed to have received a different regimen entirely, IFL (day 1 irinotecan, bolus fluorouracil, and leucovorin without the addition of 48 h of continuous infusion 5FU), which is a more toxic and less efficacious regimen. 19 More importantly, if we had ignored the DME files entirely (ie, not evaluated for evidence of 48 h of continuous infusion 5FU that is a part of the FOLFIRI regimen), fully 82% of the CALGB FOLFIRI patients would have appeared to have received IFL instead. This finding raises caution regarding studies that seek to compare outcomes of patients receiving pharmacologically similar regimens as exposures may be difficult to delineate in such instances.
Our results apply to elderly Medicare patients who are receiving their first treatment in the ambulatory setting and therefore may not apply to all elderly Medicare patients receiving the multiagent chemotherapy regimen of interest. This selection bias is introduced by the fact that individual chemotherapy agents are not discernible within inpatient Medicare claims, only treatment with "chemotherapy" broadly defined. Elderly Medicare patients with poorer performance statuses and more biologically aggressive tumors may be less likely to be represented in the ambulatory samples of patients receiving multiagent chemotherapy regimens as their care may be more often initiated in the inpatient setting (Table 3) . Thus the prognostic estimates associated with the multiagent chemotherapy regimens will apply only to those Medicare patients who begin their treatment in the ambulatory setting (ie, not all Medicare patients who receive the given multiagent chemotherapy regimen).
In conclusion, our results suggest that CMS files are highly but not perfectly sensitive for identifying elderly Medicare patients who are treated with standard multiagent chemotherapy regimens. As such, the findings may accelerate studies of the comparative effectiveness of specific multiagent chemotherapy regimens in elderly cancer patients. Such studies may allow population scientists and policy makers to understand the benefits and risks of various standard multiagent chemotherapy regimens that were developed in clinical trial settings when they are applied to elderly Medicare patients with cancer who are treated in the usual care setting.
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